I will also ask for an appropriation of an extra $100 million to launch an intensive campaign to find a cure for cancer, and I will ask later for whatever additional funds can effectively be used. The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon should be turned toward conquering this dread disease. Let us make a total national commitment to achieve this goal.
-Richard M. Nixon, State of the Union Address, January 1971 (1) H e was my first patient, but I was certainly not his first doctor. For a 28-year-old, this unfortunate man had been treated by far too many doctors. He had pre-B cell acute lymphoblastic leukemia, with cytogenetic markers that gave him a poor prognosis. He had acquired this diagnosis 18 months before I met him. During that time, he had undergone multiple rounds of chemotherapy and a bone marrow autograft, all of which had failed to hinder the progression of his disease. He had endured 16 bone marrow biopsies and had been treated for chemotherapy-induced pneumonia, septic shock, renal failure, hepatitis, dermatitis, and peripheral neuropathy. He had entered the hospital for one more desperate round of chemotherapy. He would be dead before the end of my first month as an intern.
I had met another patient earlier in my medical training, when I was a third-year medical student. She was a 56-year-old wife and mother who taught home economics at a local high school. She presented with fatigue and increased bruising and was diagnosed with acute promyelocytic leukemia. Cells in her bone marrow had undergone a genetic mutation in which parts of two of her chromosomes had exchanged material, resulting in the fusion of two genes, the promyelocytic gene and the retinoic acid receptor gene. This fusion had resulted in the overproduction of a clone of immature white cells, called promyelocytes. Fortunately for this patient, these cells were susceptible to alltrans-retinoic acid, a vitamin A derivative that activates the retinoic acid receptor, causing promyelocytes to mature and preventing them from proliferating. The patient underwent therapy with all-trans-retinoic acid and has been in complete remission for over 3½ years.
It has been over 35 years since President Nixon declared "war" on cancer. As the two cases above illustrate, this war has had its victories and its failures. In this article I describe some of the techniques that have been developed or refined over the last 35 years in this ongoing battle and provide some specific examples of how they are employed.
Improved screenIng
In most cases, cancers caught early are more amenable to treatment than those caught at later stages. The need for early cancer diagnosis has led to effective screening programs for cervical, breast, and colorectal cancers. Cytopathological screening for cervical cancer was developed by Georgios Papanicolaou at New York Hospital in the 1940s, but its use in 1971 was limited (2, 3) . Since then, increasing use of the Pap smear has had a dramatic impact on cervical cancer mortality, which decreased in the USA from 7.7 to 2.6 per 100,000 women between 1969 and 2002. Mammography also existed in 1971 but was used almost exclusively for confirmation of the existence of suspected breast cancer, not for screening (4) . Today, annual mammographic screening for women beyond age 40 or 50 is the standard of care (5) . Early detection combined with improved treatment led to a decrease in breast cancer mortality from 31.8 to 25.5 per 100,000 women between 1969 and 2002 (6) . Broad colorectal cancer screening is also a post-1971 phenomenon. The fiberoptic endoscope was invented in 1957 by Basil Hirschowitz at the University of Alabama but had not been refined enough by 1971 for general use (7) . Rigid sigmoidoscopes were employed in the diagnosis of distal lesions but were not (to the relief of patients) used for screening (8) . Today, flexible colonoscopy, flexible sigmoidoscopy, and Hemoccult tests are widely, although not universally, employed (9) (10) (11) . Improved screening and treatment has led to a decrease in overall colorectal cancer mortality from 29.4 to 19.6 per 100,000 between 1969 and 2002 (6) .
Despite the foregoing successes, adequate screening techniques for most types of cancers have not yet been developed. Moreover, some broadly employed screening tests have not proven effective. For instance, large trials have not established any survival benefit from radiologic screening for lung cancer, even among smokers (12) . Current prostate cancer screening through digital rectal examinations and measurement of prostatespecific antigen also remains controversial. It is unclear whether either test reduces morbidity or mortality (13) (14) (15) . Furthermore, equivocal results can prompt unnecessary prostate biopsies and cause increased patient anxiety (16, 17) .
vaccInaTIon To prevenT cancer
Chronic viral infections have been implicated in a number of human cancers. Examples of oncogenic viruses include hepatitis B and C, which cause hepatocellular carcinoma (18) ; certain strains of the human papillomavirus, which cause cervical cancer (19) ; the Epstein-Barr virus, a likely cofactor in the development of African Burkitt lymphoma (20) ; human herpesvirus 8, which causes Kaposi sarcoma (21); and HIV, which has been associated with non-Hodgkin lymphoma and Kaposi sarcoma (22, 23) . Immunization against these viruses could prohibit the development of the malignancies they cause. Vaccines against hepatitis B and human papillomavirus, both of which are effective preventative agents, are the first to test this proactive approach.
Persistent hepatitis B infection is clearly associated with the development of hepatocellular carcinoma (24, 25) . In nonendemic areas (including North America), the risk of hepatitis B-related hepatocellular carcinoma is relatively low (26) (27) (28) . However, in endemic areas, including Asia, China, and subSaharan Africa (29) , hepatocellular carcinoma is the most common malignancy (25) . A nationwide childhood hepatitis B vaccination program launched by Taiwan in 1984 has decreased the incidence of hepatocellular carcinoma from 0.54 to 0.20 per 100,000 children (30, 31) . Vaccination programs in other endemic areas will likely have equally dramatic results. Childhood hepatitis B vaccination is now the standard of care in this country (32) .
The development of cervical cancer is virtually always preceded by persistent infection with certain strains of human papillomavirus (19, (33) (34) (35) . A vaccine that targets these strains has been shown to prevent (over a 4½-year period) human papillomavirus-related dysplasia that can lead to cervical cancer (34, 36) . Given this finding, widespread vaccination against these strains would likely decrease the incidence of cervical cancer. However, validation of this preventive approach is years away.
geneTIc screenIng
Since the 1970s, there have been remarkable developments in the understanding of the genetic role of tumorigenesis. Molecular genetic research by Bert Vogelstein and colleagues at Johns Hopkins University in the field of colorectal cancer provides an example. In a series of experiments, Vogelstein's laboratory identified several genetic alterations that occur in an apparently stepwise fashion, causing the development of adenomatous polyps, which may then transform over many years into invasive adenocarcinoma. The initial mutations usually occur spontaneously but are inherited in certain individuals who then develop numerous polyps and have a 100% lifetime risk of colorectal cancer (37) (38) (39) . Other examples of oncogenic mutations include defects in DNA mismatch repair genes that can also cause colorectal cancer (40) and in the BRCA1 and BRCA2 genes, which often result in breast and/or ovarian cancers (41) .
The availability of genetic screening tests for these and other mutations provides an opportunity for taking action even before cancer develops. For instance, patients with BRCA1 or BRCA2 mutations may opt for increased surveillance, chemopreventive measures, or even prophylactic bilateral mastectomy and/or oophorectomy (42, 43) . However, genetic testing can be problematic. In most instances, a positive test result indicates only a predisposition to disease, not a guarantee of it. This creates much uncertainty about which preventive measures to undertake. Genetic testing is also expensive. For example, testing for DNA mismatch repair mutations costs approximately $3000 (44) . Since this is only one of a growing number of tests for genetic predisposition to malignancy, widespread screening is clearly impractical.
more precIse LaBoraTorY dIagnosIs
Until the 1970s, diagnosis of cancer was based almost entirely on conventional histopathology. The pathologist examined a tissue specimen under light microscopy and rendered a diagnosis based on various nuclear and cytoplasmic features. While such analysis is generally valuable, it is relatively nonspecific. Cells undergoing reactive changes due to inflammation or infection may have morphologic features similar to those of cells experiencing malignant transformation. Moreover, some unrelated malignancies have a similar appearance by light microscopy (45) . Since the 1970s, cancer diagnosis has been revolutionized by the development of a number of sophisticated laboratory techniques, greatly enhancing the ability of oncologists to more accurately target their therapies (22) . Examples of these techniques include immunohistochemistry, flow cytometry, and the polymerase chain reaction (PCR).
Immunohistochemistry was made possible by the development of hybridoma technology in the 1970s by Cesar Milstein and George Kohler of Cambridge University, work for which they shared a Nobel Prize (46) . This technology allows for the mass production of monoclonal antibodies, which bind antigens commonly found on the surfaces of malignant cells (47) . After binding, immunohistochemical stains are employed to identify and quantify the antigen. Monoclonal antibodies are well characterized and provide reproducible data. While individual monoclonal antibodies are not tumor specific, panels of monoclonal antibodies, when interpreted together, can often provide enough data to generate a diagnosis. Immunohistochemical staining is also used to identify tumor markers-such as carcinoembryonic antigen, alpha-fetoprotein, prostate-specific antigen, CA 19-9, CA 125, thyroid transcription factor-1, the erb-B2 oncoprotein, and estrogen and progesterone receptors-that suggest a diagnosis, have prognostic value, and/or may direct treatment options (48) (49) (50) . As discussed below, targeted monoclonal antibodies are also being employed in cancer therapy.
Flow cytometry allows for rapid, simultaneous analysis of multiple cellular characteristics. The cells in question are stained with fluorochromes, suspended in an aqueous buffer, and then passed through a flow chamber where they are struck by laser beams. Light scatter and fluorescent emissions from these particles are then captured by detectors and converted into electronic signals, which are then quantified by computer. DNA and RNA can be measured by using fluorochromes that bind particular nucleic acid sequences. Antigens in or on cells can also be assessed using fluorochromes attached to monoclonal antibodies. Cell size and volume are assessed by light scatter. Because modern flow cytometers can simultaneously analyze many cells, this technology is well suited for the examination of the properties of a population of cells. It is particularly useful for analyzing bone marrow, where leukemic cells may be interspersed with normal cells. Consequently, flow cytometry has evolved into a vital tool in the diagnosis, classification, and management of acute and chronic leukemias and lymphomas (51, 52) .
PCR, which was developed by Kary Mullis (also resulting in a Nobel Prize), allows for the rapid, exponential in vitro amplification of target DNA or RNA (53) . In only a few hours, PCR amplification can produce approximately 100 billion copies of one molecule of DNA. Once amplified, PCR products are then assessed using other techniques, such as electrophoresis, direct staining, or Southern blot hybridization. PCR can be used, often with great sensitivity and specificity, to identify chromosome translocations or cytogenetic abnormalities that are known to be associated with particular malignancies (54, 55) . Besides aiding in primary diagnosis, PCR-based techniques are also employed to direct cancer therapy. One example is the Oncotype DX assay, a reverse transcriptase-PCR method that evaluates the expression of 16 genes whose increased or decreased expression correlates with the risk of disease recurrence in early stage estrogen receptorpositive breast cancer patients. By characterizing the recurrence risk, this assay can help determine whether such patients should be treated with adjuvant (postoperative) tamoxifen alone or should undergo adjuvant chemotherapy prior to tamoxifen therapy (56) . Other significant cytogenetic diagnostic laboratory techniques that have been developed since 1971 include fluorescence in situ hybridization, Southern blot and Northern blot hybridization, and DNA microarray technology (22, 57) .
BeTTer ImagIng
To be appropriately treated, a tumor must be detected and then staged. Tumor stage is determined by evaluating the size of the primary tumor, the extent of regional lymph node involvement, and the existence of distant metastases. Staging is critical because prognosis and treatment options vary by stage (58, 59) . In 1971, there were few noninvasive tools for detecting neoplasms or assessing the degree of tumor dissemination (60) . Since then, cancer detection and treatment have been revolutionized by the development of new imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomographic (PET) scanning.
CT was jointly developed by Allan MacLeod Cormack of Harvard and Sir Godfrey Hounsfield of Electrical and Musical Instrument, Ltd. (61) . Electrical and Musical Instrument reportedly used funds from the sale of Beatles albums to fund this research (62) . This technology employs a narrow x-ray beam that rotates around the body, producing multiple twodimensional "slices" that are then processed by computer into a three-dimensional image (63) . CT was first introduced in 1971 and gained rapid acceptance soon thereafter. In 1979, Cormack and Hounsfield shared a Nobel Prize for its development (61) . Modern high-resolution CT scanners represent a significant advance over routine radiographic studies in assessing tissue density, distinguishing subtle variances between adjacent structures, and characterizing lesion size (64) . These scanners are now routinely employed to detect malignant lesions, assess tumor stage, and evaluate treatment response (65) . As discussed below, CT scanners are also utilized in the planning and delivery of radiation therapy.
MRI was developed in the 1970s by Paul Lauterbur of the State University of New York and Sir Peter Mansfield of the University of Nottingham, resulting in a 2003 Nobel Prize. With this technology, a computer is used to generate a threedimensional image based on differences in oscillating electrical currents emitted by atomic nuclei within the human body that have been subjected to a strong magnetic field, which forces them to align, and then excited by external radiofrequency electromagnetic pulses (66) . MRI can often provide significant contrast between tumors and surrounding soft tissues and is now employed as a first-line diagnostic tool in evaluating central nervous system and musculoskeletal neoplasms. It has also proven useful in locating and characterizing vascular, hepatobiliary, pelvic, and head and neck tumors (65) .
PET is a nuclear imaging technique that detects areas of increased metabolic activity. This technology uses short half-life radionuclides attached to molecules of glucose. After injection, glucose becomes concentrated in metabolically active sites, such as those undergoing neoplastic proliferation, and these areas are then detected when the attached radionuclides emit gamma radiation. PET scans can detect CT-indeterminate primary lesions with >90% sensitivity (67) . However, PET imaging can produce false-positive findings in areas that have increased metabolic activity due to infection, inflammation, or granulomatous disease. Consequently, positive findings still require a biopsy (as do lesions noted by CT or MRI). PET scanning is now widely employed in both detecting primary cancers and ascertaining response to therapy (68) . While PET scans can detect images not observable by CT, they provide limited anatomic resolution when used alone. Integrated PET-CT scanners have recently been developed, synergizing the benefits of these dual technologies for more accurate diagnosis, staging, and monitoring (69) .
Improved cYToToxIc chemoTherapY
Improved multidrug chemotherapy regimens have had dramatic results in the treatment of many different malignancies. Treatment of metastatic germ cell testicular cancer provides an example. Germ cell tumors are broadly categorized into seminomas and nonseminomas (70) . The standard of care in 1971 and today for both types of tumors involves radical orchiectomy (71, 72) . Seminomas were also often irradiated (71), as they are today (73, 74). However, it had already been recognized prior to 1971 that nonseminomas, which constitute a majority of germ cell tumors, were less radiosensitive (71) . Because effective chemotherapy did not exist, patients with metastatic nonseminomas faced a 5% chance of survival. In the 1970s, Lawrence Einhorn and colleagues at Indiana University developed a chemotherapy regimen that included three different drugs, each with a separate mechanism of action and nonoverlapping toxicity. The drugs worked synergistically, and his regimen, which has been refined over time, now has an 80% cure rate for metastatic nonseminomas. Advanced seminomas are now also treated the same way (75, 76) .
Chemotherapy has also been improved by the development of new classes of cytotoxic agents, as exemplified by the taxanes. First introduced in the early 1990s, these agents work by disrupting microtubule disassembly, a critical stage of cell division. By arresting cells in this premitotic G2 phase, which is the most radiosensitive phase of the cell cycle, taxanes are considered good radiosensitizing agents (77) (78) (79) . Taxanes have been successfully employed in the treatment of a number of solid tumors. When combined with a platinum analog, the taxane paclitaxel has been shown to significantly improve rates of overall response, clinical complete remission, progression-free survival, and overall survival in patients with advanced ovarian cancer (80) . Taxanes have also shown benefit as single agents in recurrent ovarian cancer and are used to treat cancers of the breast (81), lung (82), head and neck (83) , and prostate (84) .
TargeTed TherapY
Growing understanding of the protein structure and biochemical mechanisms of some cancers has led to the development of a number of targeted therapeutic approaches. Unlike cytotoxic regimens, which damage healthy as well as malignant cells, these therapies are designed to inhibit specific neoplastic pathways. By doing so, they offer the possibility of increased efficacy and better tolerability, allowing them to be used in a broader range of patients. As discussed above, the use of alltrans-retinoic acid therapy in the treatment of acute promyelocytic leukemia is one example of targeted therapy. The use of imatinib mesylate in the treatment of chronic myelogenous leukemia is another. Chronic myelogenous leukemia results from a balanced translocation between parts of two chromosomes (9 and 22), resulting in the fusion of the BCR and ABL genes (the Philadelphia chromosome). ABL is a tyrosine kinase, an enzyme that causes the transmission of growth signals to the cell nucleus. Fusion with BCR results in upregulation of this signal transduction and, through mechanisms not yet fully understood, the development of chronic myelogenous leukemia (85) . The oral agent imatinib mesylate blocks this process. Short-term results from treatment of Philadelphia chromosome-positive patients with imatinib have been promising. In one series, 97% of patients treated with imatinib had no evidence of chronic myelogenous leukemia in their peripheral blood at 18 months, a "complete hematological response." Fifty-three percent of patients in this series had a complete cytogenic response, defined as absence of Philadelphia chromosome by fluorescence in situ hybridization (86) . Longer-term follow-up is pending. The extraordinary success of imatinib has led some physicians to call this drug the "penicillin" of oncology. Targeted therapy also includes a growing number of monoclonal antibodies, as discussed below.
hormonaL TherapY
The link between hormones and the development of breast and prostate cancers was established well before 1971. Thomas William Nunn first suggested a connection between the ovaries and the development of breast cancer in the late 1800s, many years before the discovery of estrogen. Surgical oophorectomy as a treatment for breast cancer was proposed soon thereafter (87) . In the 1940s, Charles Huggins and colleagues at the University of Chicago demonstrated that advanced prostate cancers could be palliated by testosterone deprivation, either directly through orchiectomy or indirectly by the administration of estrogen, which suppresses production through negative feedback on the hypothalamic-pituitary axis (88) . Huggins received the Nobel Prize for this work (89) . In the 1950s, Huggins described the role of estrogen in the development of breast cancer and showed that some breast cancers could be palliated by estrogen deprivation, through oophorectomy and adrenalectomy (90) .
In 1971, hormonal therapy was reserved for advanced breast cancer. Estrogen deprivation was achieved through oophorectomy, adrenalectomy, or hypophysectomy. It was also accomplished by administration of testosterone, which inhibits pituitary gonadotropin secretion (91, 92) . Today, estrogen inhibition therapy is used in early stage and advanced breast cancers. Testosterone has fallen out of favor and surgical estrogen deprivation plays a more limited role due to the development of a number of estrogen-blocking agents, including tamoxifen, various aromatase inhibitors, and several luteinizing hormonereleasing hormone (LHRH) agonists. Tamoxifen is a selective estrogen receptor modulator that blocks the action of estrogen at its receptor site. Aromatase inhibitors act upstream by inhibiting the synthesis of estrogen. Aromatase inhibitors are used only in postmenopausal women, because the estrogen deprivation they cause leads to increased ovarian stimulation in premenopausal women. Both tamoxifen and aromatase inhibitors reduce relapse rates in hormone receptor-positive breast cancer and improve survival in metastatic disease (93) (94) (95) (96) (97) . Tamoxifen also reduces the incidence of breast cancer in patients at high risk of this disease (98, 99) . LHRH agonists suppress the pituitaryovarian axis when administered in a continuous fashion, leading to decreased estrogen synthesis (100). Thus, they are a chemical alternative to surgical ovarian ablation. LHRH agonists are effective adjuvant agents for hormone receptor-positive early stage breast cancer in premenopausal women (101) . LHRH agonists are also indicated for the treatment of premenopausal women with metastatic disease (100) .
As it has with breast cancer, medical antihormonal therapy has reduced the role of surgical castration in the treatment of prostate cancer. Androgen deprivation therapy is now accomplished by a variety of methods, including continuous LHRH agonist therapy, LHRH antagonists, and various antiandrogens (102) . Androgen deprivation therapy has a limited role in early stage disease, where it may be employed neoadjuvantly (preoperatively) or as a definitive treatment (103) . Androgen deprivation therapy is employed first-line in metastatic disease, where it is used with palliative intent (104) .
Immune TherapY
It was first recognized in the 1700s that certain cancer patients experienced regression of their disease when they developed concurrent bacterial infections. Over 100 years ago, William Coley attempted to harness this immune regulation of cancer through the deliberate inoculation of cancer patients with several bacterial strains. Coley achieved a number of durable remissions, particularly in patients with soft tissue sarcomas (105) . However, in the preantibiotic era, his patients experienced considerable complications from this treatment, and clinical interest in "Coley's vaccine" diminished after his death (106, 107) . Since the 1980s, interest in immune therapy of cancer has greatly expanded, leading to the development of a number of biologic agents, including interferon alfa and interleukin 2 (108) . Therapy with interferon alfa, a recombinant cytokine derived from leukocytes, can achieve demonstrable response rates in several cancers, including metastatic melanoma (109), metastatic renal cell carcinoma (110) , multiple myeloma (111), chronic myelogenous leukemia (112) , and hairy cell leukemia (113) . Interleukin 2, another cytokine, has shown benefit in the treatment of metastatic renal cell carcinoma and melanoma (114) . While the response rates for current immune therapy regimens are low and the side effects are significant, certain subsets of patients who do respond have experienced extended disease-free intervals (112, 115, 116) .
Monoclonal antibodies represent another form of immune therapy. As discussed above, monoclonal antibodies can be designed to bind specific proteins on the surface of malignant cells, allowing for more precise diagnosis. They can also be formulated to bind and inhibit or kill malignant cells. Several of these agents are now being employed clinically. One is rituximab, a monoclonal antibody that binds the CD20 antigen found on the surface of more than 90% of B-cell lymphomas, causing cell death through mechanisms not yet fully elucidated (117) . Rituximab has shown benefit as a single agent in the treatment of newly diagnosed or relapsed low-grade follicular non-Hodgkin lymphoma (118) (119) (120) and when combined with cytotoxic chemotherapy in the treatment of follicular, mantle cell, and diffuse aggressive non-Hodgkin lymphomas (121) (122) (123) .
Another widely employed therapeutic monoclonal antibody is trastuzumab, which is directed against the c-erbB-2 protein, a product of the HER-2/neu oncogene. HER-2/neu overexpression, which occurs in approximately one third of breast cancers, has been associated with a poor prognosis (124, 125) . The exact mechanism of action of trastuzumab remains to be discerned, but its clinical benefit is clear. Trastuzumab has been used effectively as a single agent and in combination with cytotoxic chemotherapy in patients with HER-2/neu-positive metastatic disease (126, 127) . More recently, preliminary data from several large randomized trials have suggested that the addition of trastuzumab to standard chemotherapy in early stage high-risk HER-2/neu-positive breast cancer patients may significantly increase disease-free survival (128, 129) .
The recognition of the immune regulation of cancer has also generated interest in vaccine cancer therapy. This is essentially a modern extension of Coley's work. While this approach is promising, it is too soon to tell whether it will be of benefit (130, 131) .
anTIangIogenesIs
Tumors cannot grow beyond 2 to 3 mm in diameter without the development of new blood vessels (132) . In a seminal 1971 article in the New England Journal of Medicine, Judah Folkman of Harvard Medical School proposed that inhibition of this angiogenesis could limit tumor growth (133) . In recent trials, bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF), the dominant growth factor that controls angiogenesis, has been shown to significantly improve survival and delay disease progression when used in combination with systemic chemotherapy in patients with advanced colorectal cancer (134, 135) .
While bevacizumab neutralizes VEGF itself, other novel agents bind and inhibit the VEGF receptor site, blocking the activity of VEGF. The two most heavily investigated VEGFreceptor inhibitors are the small molecules sorafenib and sunitinib, which have been employed in the treatment of metastatic renal cell carcinoma (136, 137) . Numerous trials are investigating the effectiveness of bevacizumab, sorafenib, sunitinib, and other angiogenesis inhibitors in the treatment of various solid tumors.
radIaTIon TherapY
Radiation therapy for cancer was developed soon after the discovery of x-rays by Wilhelm Conrad Röntgen in 1895 (22) . By 1971, it had already been established that a number of solid tumors were radiosensitive (138) . Since then, radiation therapy has undergone many refinements. Clinical trials have established evidence-based protocols for its application alone or as an adjuvant or neoadjuvant treatment for a variety of cancers (139) . In some regimens, chemotherapeutic agents (such as the taxanes) are now used as radiosensitizers to maximize the tumor-killing effect of radiation (140) . This approach has shown benefit in the treatment of a number of cancers, including head and neck cancer (141) , non-small cell lung cancer (142), esophageal cancer (143), cervical cancer (144) , and anal cancer (145) .
There have also been significant advancements in the planning and delivery of radiation. Specialized CT scanners now permit more precise placement of radiation fields (146, 147) . This process has been further refined by the use of three-dimensional conformal radiotherapy, in which radiation is controlled in different planes based on the shape of the targeted tumor. With this technique, increased radiation can be delivered to the tumor site, while damage to surrounding tissues can be minimized (140, 148) . A more recent development is intensity-modulated radiotherapy, in which the strength of a radiation beam can be varied over a particular area. This further increases precision and may allow for the radiation of tumors attached to vulner-able structures, such as the spinal cord, where radiation therapy might otherwise be too dangerous (149) . With stereotactic radiosurgery, an intense and precise radiation dose can be delivered to a small tumor area. This modality has proven useful in the treatment of small (<3 cm) brain lesions, where radiation to adjacent structures is unacceptable (150) . It has also shown benefit in the treatment of early stage non-small cell lung cancer in patients who are not surgical candidates (151) .
Bone marrow TranspLanTaTIon
In 1959, E. Donnall Thomas and colleagues at Columbia University achieved a 12-week remission in a young patient with end-stage acute leukemia by transplanting marrow from her identical twin sister (152) . Thomas later received a Nobel Prize for his pioneering work in bone marrow transplantation (153) . The first successful marrow transplantations using human leukocyte antigen-matched sibling donors occurred in the early 1970s. In the 1990s, improved molecular genotyping allowed for precise characterization of major histocompatibility complex genes, making possible transplant between unrelated donors (154) . During this time, techniques to harvest hematopoietic stem cells from peripheral blood stem cells and from umbilical cord blood were developed (155, 156) .
Standard preparative regimens for transplantation involve complete ablation of bone marrow through high-dose chemotherapy with or without radiation. This highly toxic approach limits graft-versus-host disease but results in considerable morbidity and mortality (157, 158) . More recently, lower-dose, nonmyeloablative conditioning regimens have shown promise. These regimens may reduce relapse through the graft-versus-tumor effect of donor cells (159) . The decreased toxicity of these regimens also allows for their use in higher-risk patients (160) . Bone marrow transplant is now routinely employed in the treatment of acute myelogenous leukemia (161) and in more limited instances in other hematologic malignancies, including acute lymphoblastic leukemia (162) , chronic myelogenous leukemia (163) , chronic lymphocytic leukemia (164), Hodgkin disease (165), follicular non-Hodgkin lymphoma (166) , and multiple myeloma (167) (168) (169) .
Less morBId TreaTmenTs
In some instances, cancer therapy has been improved by tailoring treatments to reduce patient morbidity. One example of this is in the management of breast cancer. The standard of care for breast cancer in 1971 was radical mastectomy, a debilitating procedure. While the radiosensitivity of many breast carcinomas had been established by that time, radiotherapy was generally offered only as an adjunct to mastectomy (170) . Since then, several large randomized studies have shown equivalent survival in early stage breast cancer between patients treated with mastectomy and those given breast-conserving lumpectomy with adjuvant radiotherapy and axillary lymph node dissection (171, 172) . Many women now opt for this less morbid approach. Other reduced morbidity treatments include "watchful waiting" for some low-grade prostate cancers and indolent non-Hodgkin lymphomas (173, 174) , increased use of targeted medical therapies, limb-sparing surgery for certain osteosarcomas and soft tissue sarcomas (175) , and sentinel lymph node biopsy in the staging and management of some breast cancers, melanomas, and head and neck cancers (176) (177) (178) .
Improved supporTIve measures
Life-threatening anemia and infections commonly occur in many hematological malignancies and in some solid tumors (179) . These complications generally result from chemotherapeutic ablation of bone marrow, which may already be compromised by the underlying cancer (180) . Transfusion therapy and broad antimicrobial regimens are now widely employed to mitigate these complications. Transfusion therapy is more effective and more widely available than it was in 1971 due to improvements in the collection, separation, and preparation of packed red cells and platelets. In many centers, packed red cells and platelets are now filtered to reduce the number of leukocytes. Leukocyte reduction decreases transfusion reactions, antibody production, and cytomegalovirus transmission (181). Blood products can also be irradiated, further reducing donor lymphocytes (182, 183) . Packed red cells and platelets are now routinely transfused in anemic and thrombocytopenic patients (184) . Antimicrobial therapy has improved considerably since the 1970s. Newer agents offer broader and more potent coverage. Monotherapy has been replaced by more effective multidrug regimens (185) . Neutropenic patients are now treated empirically with broad-spectrum antibacterial, antifungal, and antiviral regimens. Antimicrobial coverage is further expanded at the first sign of infection (186, 187) . These measures have had a significant impact on the survival of patients undergoing myelosuppressive chemotherapy (179, 180, 188) .
Patient support has also been improved by the development of hematopoietic growth factors, which stimulate the proliferation and differentiation of hematopoietic stem and progenitor cells. Anemic cancer patients are often treated with recombinant human erythropoietin, which triggers erythrocyte production and has been shown to reduce cancer-related fatigue and the necessity for transfusion (189) . Patients with chemotherapy-induced neutropenia are sometimes treated with recombinant human granulocyte colony-stimulating factor (G-CSF), which converts granulocyte colony-forming units into polymorphonuclear leukocytes. G-CSF has been shown to reduce the risk of febrile neutropenia and infection. However, the overall clinical benefit of this therapy is controversial. In one study, the administration of G-CSF was shown to shorten the duration of antibiotic use and overall hospitalization in patients with "high-risk" neutropenia, defined as an absolute neutrophil count of <100/mm 3 , short latency from previous chemotherapy cycle (<10 days), sepsis or clinically documented infection at presentation, severe comorbidity, poor performance status, or prior inpatient status. However, there was no difference in the incidence of severe medical complications or mortality (190) . Other studies that did not focus on such high-risk patients found no mortality benefit or improved response to antibiotics when G-CSF was employed either as primary prophylaxis or as a treatment for neutropenic fever (191) (192) (193) . Consequently, G-CSF is generally reserved for patients at high risk of neutropenia or those undergoing bone marrow transplantation (194) .
The FuTure
It has been only 50 years since Hertz and colleagues at the National Institutes of Health first demonstrated that a particular type of metastatic cancer, choriocarcinoma, could be cured with chemotherapy (195) . As evidenced by an overall decline in cancer mortality and increase in postdiagnosis survival (Table) , there has been significant progress since then (196) . There is little doubt that we will make further advances as we gain increasing understanding of the cytogenetics, pathogenesis, and biochemical characteristics of solid tumors and hematologic malignancies. More types of cancer will become curable. Others will become controllable. Many patients will benefit from these advances. Nevertheless, as we move forward, our successes will be tempered by the memory of those, like my first patient, for whom progress came too late. 
